BRISBANE, Calif. -- Spiral Therapeutics, a clinical stage pharmaceutical company delivering therapies for hearing loss, today announced the final closing of its Series A financing, bringing the total amount raised in…

Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today announced the initiation of its Phase 1 clinical trial of LPT99, the company's lead investigational drug candidate targeting prevention…

Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, announced the initiation of its Phase 1 clinical trial of LPT99, the company’s lead investigational drug candidate targeting prevention and treatment…

Spiral Therapeutics, Inc., a biopharmaceutical company developing first-in-class therapies targeting inner ear disorders, reported positive feedback from the US Food and Drug Administration (FDA) in response to Spiral's first pre-Investigational…